The retail price of pomalidomide in domestic pharmacies in 2025

Pomalidomide (Pomalidomide), as an important immunomodulator in the treatment of multiple myeloma, has been increasingly used in the Chinese market in recent years. In 2025, pomalidomide has been officially launched in China and has been included in the national medical insurance directory, which provides a more convenient medication channel for the majority of patients. Patients can purchase the drug through pharmacies of regular medical institutions and obtain legal and compliant drug protection.

Despite being included in medical insurance, the domestic retail price of pomalidomide is still relatively high. The specific price varies depending on the medical insurance policies and hospital procurement conditions in different regions. Generally speaking, the selling price of each box of medicine is still at a high level. When actually purchasing, patients are advised to go to the local hospital pharmacy to inquire about the specific price and medical insurance reimbursement ratio, so as to understand their own financial burden and reimbursement policy, and arrange a reasonable medication plan.

Compared with the high domestic prices, there are some more affordable generic versions in foreign markets. In particular, generic drugs from Laos sell for about more than 300 yuan per box. The lower price advantage of these generic drugs has attracted some patients to obtain medicines through overseas channels. However, purchasing drugs overseas involves many risks such as legality, drug quality, and after-sales service. Patients should carefully weigh the pros and cons.

Overall, the launch of pomalidomide in the Chinese market and its inclusion in medical insurance have greatly improved the accessibility of the drug, but the price is still high, which puts certain financial pressure on patients. With the development and marketing of generic drugs, it is expected that through policy optimization and market competition, drug prices will be further reduced, patients' burden will be reduced, and the popularity and effectiveness of treatment will be improved.

Reference materials:https://www.drugs.com/